Современные диагностические методы в эндокринологии

Широко используемые диагностические методы, применяемые в современной медицине, такие как компьютерная томография (КТ) и ядерный магнитный резонанс (ЯМР), в настоящее время стали рутинными. Новым, перспективным методом диагностики, появившимся в последнее время, является позитронно-эмиссионная томография (ПЭТ).

1. Czernin J, Phelps ME 2002 Positron emission tomography scanning: current and future applications. Аппи Rev Med 53:89-112.

2. Mankoff DA, Bellon JR 2001 Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 11:16-27.

3. Shreve PD, Anzai Y, Wahl RL 1999 Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61-77.

4. Grierson JR, Shields AF 2000 Radiosynthesis of 3Ldeoxy-3'-[18F]fluo-rothymidine: [18F]FLT for imaging of cellular proliferate in vivo. Nucl Med Biol 27:143-156.

5. Vaalburg W, Coenen HH, Crouzel C, Elsinga PH, Langstrom B, Lemaire C, Meyer GJ 1992 Ammo acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B 19: 227-237.

6. Willemsen AT, van Waarde A, Paans AM, Pruim J, Luurtsema G, Go KG, Vaalburg W 1995 1п vivo protein synthesis rate determination in primary or recurred brain tumors using L-[1-11C]-tyrosine and PET. J Nucl Med 36:411-419.

7. Lewis JS, Welch MJ 2001 PET imaging of hypoxia. Q J Nucl Med 45:183-188.

8. HaubnerR, Wester HJ, WeberWA, Mang C,Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M 2001 Noninvasive imaging of a(v)/33 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-1785.

9. Blankenberg FG, Tait J, Ohtsuki K, Strauss HW 2000 Apoptosis: the importance of nuclear medicine. Nucl Med Commun 21:241-250.

10. Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS 2001 6-[18F]Fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromo-cytoma. Hypertension 38:6-8.

11. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstem DS 2001 Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intem Med 134:315-329.

12. Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Lang-strom B 2000 Use of PET in neuroendocrine tumors. 1п vivo applications and in vitro studies. Q J Nucl Med 44:68-76.

13. Muhr C, Bergstrom M1991 Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest 14:509 -528.

14. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, Larson SM 2002 Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imagmg and receptor mediated intemal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29:147-157.

15. Hofmann M, Maecke H, Bomer R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H 2001 Biokinetics and imagmg with the somatostatm receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 28: 1751-1757.

16. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY 1999 Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40:986-992.

17. Grunwald F, Kalicke T, Feme U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ 1999 Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547-1552.

18. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL 1993 Uptake of 18-flu-oro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 77:1090-1094.

19. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ 1999 [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scam and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302.

20. Ladenson PW, Ewertz ME, Dickey RA 2001 Practical application of recombinant thyrotropin testiHg in clinical practice. Endocr Pract 7:195-201.

21. Robbms RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM 2002 Is the serum thyroglobulm response to recombinant human thyro-tropin sufficient, by itself, to monitor for residual thyroid carcmoma? J Clm Endocrinol Metab 87:3242-3247.

22. Robbms RJ, Tuttle RM, Sharaf RN, Larson SM, Robbms HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recom-binant human thyrotropin or thyroid hormone withdrawal are comparable for the detects of residual differentiated thyroid carcmoma. J Clm Endocrinol Metab 86:619-625.

23. Wartofsky L 2002 Using baseline and recombinant human TSH-stim-ulated Tg measurements to manage thyroid cancer without diagnostic 131I scanning. J CliH Endocrinol Metab 87:1486-1489.

24. Dietlem M, Scheidhauer K, Voth E, Theissen P, Schicha H 1997 Fluorme-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24:1342-1348.

25. Feme U 1998 Fluor-18-deoxyglucose postal emission tomography in differentiated thyroid cancer. Eur J Endocrinol 138:492-496.

26. Gru?nwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, Franckson T, Biersack HJ 1997 Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer Thyroid 7:327-335.

27. McDougall IR, Davidson J, Segall GM 2001 Postal emission tomography of the thyroid, with an emphasis on thyroid cancer. Nucl Med Commun 22:485-492.

28. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K 2000 Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989-1995.

29. Voth E, Bomer AR, Theissen P, Schicha H 1994 Positron emission tomography (PET) in benign thyroid diseases. Exp Clin Endocrinol 102:71-74.

30. Boland GW, Lee MJ, Gazelle GS, Halpem EF, McNicholas MM, Mueller PR 1998 Characterization of adrenal masses usmg unen-hanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171:201-204.

31. Dunnick NR, Korobkin M 2002 Imaging of adrenal incidentalo-mas: current status. AJR Am J Roentgenol 179:559-568.

32. Korobkin M, Brodeur FJ, Yutzy GG, Francis IR, Quint LE, Dunnick NR, Kazerooni EA 1996 Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 166:531-536.

33. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR, Raghupathi KI2002 Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 222:629-633.

34. Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M 2001 The diagnostic role of radionuclide imaging in evaluation of patients with nonhyper-secreting adrenal masses. J Nucl Med 42:884-892.

35. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A 2001 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42:1795-1799.

36. Dwamena BA, Kloos RT, Fendrick AM, Gross MD, Francis IR, Korobkin MT, Shapiro B 1998 Diagnostic evaluation of the adrenal inci-dentaloma: decision and cost-effectiveness analyses. J Nucl Med 39:707-712.

37. Gross MD, Shapiro B, Francis IR, Glazer GM, Bree RL, Arcomano MA, Schteingart DE, McLeod MK, Sanfield JA, Thompson NW 1994 Scintigraphic evaluation of clinically silent adrenal masses. J Nucl Med 35:1145-1152.

38. Lumachi F, Zucchetta P, Marzola MC, Bui F, Casarrubea G, An-gelini F, Favia G 2002 Usefulness of CT scan, MRI and radiocho-lesterol scintigraphy for adrenal imaging in Cushing's syndrome. Nucl Med Commun 23:469-473.

39. Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Ak-erstrom G, Langstrom B 2000 PET imaging of adrenal cortical tumors with the 11/3-hydroxylase tracer 11C-metomidate. J Nucl Med 41:275-282.

40. Bergstrom M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C, Langstrom B 1998 In vitro and in vivo primate evaluation of carbon-11-etomi-date and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39:982-989.

41. Erasmus JJ, Patz Jr EF, McAdams HP, Murray JG, Herndon J, Coleman RE, Goodman PC 1997 Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168:1357-1360.

42. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR, Neumann RD 1993 Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 34:173-179.

43. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, Rosenspire KC, Shapiro B, Sisson JC, Kuhl DE 1992PET scanning with hydroxyephedrine: an approach to the localization of pheochro-mocytoma. J Nucl Med 33:1125-1131.

44. Shapiro B, Gross MD, Shulkin B 2001 Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12:469-475.

45. Eisenhofer G 2001 The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 91:35-62.

46. Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ 2001 [123I]Metaiodobenzylguanidine and [111In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86:685-693.

47. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E, Neumann HP 2002 Pheochromocytomas: detection with 18F DOPA whole-body PET-initial results. Radiology 222:507-512.

48. Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB 2001 Comparison of somatostatin analog and metaiodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86:895-902.

49. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC 1993 Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731.

50. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A 2001 Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol 12:S51-S861.

51. Sundin A, Eriksson B, Bergstrom M, Bjurling P, Lindner KJ, Oberg K, Langstrom B 2000 Demonstration of [ C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27:33-41.

52. Eriksson B, Bergstrom M, Lilja A, Ahlstrom H, Langstrom B, Oberg K 1993 Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors. Acta Oncol 32:189-196.

53. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G 1998 Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83.

54. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Itoh K, Imamura M, Konishi J 2000 Evaluation of pancreatic islet cell tumors by fluorine-18 fluo-rodeoxyglucose positron emission tomography: comparison with other modalities. Clin Nucl Med 25:115-119.

55. Perrier ND, Ituarte PH, Morita E, Hamill T, Gielow R, Duh QY, Clark OH 2002 Parathyroid surgery: separating promise from reality. J Clin Endocrinol Metab 87:1024-1029.

56. Giordano A, Rubello D, Casara D 2001 New trends in parathyroid scintigraphy. Eur J Nucl Med 28:1409-1420.

57. Arkles LB 2002 Preoperative localization of parathyroid adenomas: the protagonist's view. Intern Med J 32:179-182.

58. O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ 1992 Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med 33:313-318.

59. Dijkstra B, Healy C, Kelly LM, McDermott EW, Hill AD, O'Higgins N 2002 Parathyroid localisation-current practice. J R Coll Surg Edinb 47:599-607.

60. Fraker DL 2000 Update on the management of parathyroid tumors. Curr Opin Oncol 12:41-48.

61. Neumann DR, Esselstyn CB, Maclntyre WJ, Go RT, Obuchowski NA, Chen EQ, Licata AA 1996 Comparison of FDG-PET and sestamibi-SPECT in primary hyperparathyroidism. J Nucl Med 37:1809-1815.

62. Melon P, Luxen A, Hamoir E, Meurisse M 1995 Fluorine-18-flu-orodeoxyglucose positron emission tomography for preoperative parathyroid imaging in primary hyperparathyroidism. Eur J Nucl Med 22:556-558.

63. Neumann DR, Esselstyn CB, Kim EY 1996 Recurrent postoperative parathyroid carcinoma: FDG-PET and sestamibi-SPECT findings. J Nucl Med 37:2000-2001.

64. Lucignani G, Losa M, Moresco RM, Del Sole A, Matarrese M, BettinardiV,Mortini P, Giovanelli M, Fazio F1997 Differentiation of clinically non-functioning pituitary adenomas from meningio-mas and craniopharyngiomas by positron emission tomography with [18F]fluoro-ethyl-spiperone. Eur J Nucl Med 24:1149-1155.

65. Bergstro?m M, Muhr C, Jossan S, Lilja A, Nyberg G, Langstrom B 1992 Differentiation of pituitary adenoma and meningioma: visualization with positron emission tomography and [11C]-L-deprenyl. Neurosurgery 30:855-861.

66. Muhr C, Bergstro?m M, Lundberg PO, Bergstrom K, Hartvig P, Lundqvist H, Antoni G, Langstrom B 1986 Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiper-one. J Comput Assist Tomogr 10:175-178.

67. Briele B., Hotze A., Kropp J., et al. // Nuklearmedizin 1991 Vol. 30. -P. 115 124.

68. Detlein M., Scheidhauer K. // Eur J Nucl Med 1997 Vol. 24. -P. 1342 1348.

69. Feine U., Lietzenmayer R., Hanke J.P., et al. // Nuklearmedizin 1995 Vol. 34. P. 127 134.

70. Grunwald F., Menzel C., Bender H., et al. // J Nucl Med 1998 Vol. 39 P. 1903 1906.

71. Grunwald F., Pakos E., Bender H., et al. // J Nucl Med 1998 Vol. 39. P. 1555 1558.

72. Grunwald F., Schomburg A., Bender H., et al. // Eur J Nucl Med -1996 Vol. 23. P. 312 319.

73. Menzel C., Gunwald F., Schomburg A., et al. // J Nucl Med 1996 -Vol. 37. P. 1496-1503.

74. Moog F., Linke R., Manthey N., et al. // J Nucl Med 2000 Vol. 41. P.1989 1995.

75. Petrich T., Borner A.R., Otto D., et al. // Eur J Nucl Med 2002 Vol. 29. P. 641 647.

76. Raue F. // Der Nuklearmediziner 1995 Vol. 3. P. 147 152.

77. Simon D., Korber C., Krausch M., et al. // Eur J Nucl Med Mol Imaging -2002 Vol. 29. P. 775 782.

78. Sisson J.C., Ackermann R.J., Meyer M.A., et al. // Clin Endocrinol Metab 1993 Vol. 77. P. 1090 1094.

79. Van den Bruel A., Maes A. // Clin Endocrinol Metab 2002 Vol. 87. P. 1517 1520.

80. Wang W., Macapinlac H., Larson S.M. et al. // J Clin Endocrinol Metabol 1999 Vol. 84. P. 22912302.